AZN
ACCE-researchedOverview
ACCE thesis
AstraZeneca develops and commercializes prescription medicines across oncology, rare diseases, respiratory, cardiovascular, renal, metabolism, and vaccines, with particular strength in cancer immunotherapy through drugs like Tagrisso and Imfinzi. The company's oncology franchise generates over $15 billion annually and benefits from durable patent protection on key assets, while its rare disease portfolio commands premium pricing with limited competition. Management expects the recently launched RSV vaccine Arexvy to reach blockbuster status within three years, adding to momentum from diabetes drug Farxiga which posted 35% growth in Q3. Despite trading at 31x forward earnings, AZN generates 23.5% ROE with 81% gross margins, and the pipeline includes 185 projects with multiple late-stage oncology combinations that could drive growth beyond 2030. The stock has lagged peers by 15% over the past year despite accelerating revenue growth, creating an entry point into pharma's most consistent growth story.
- moderateEarnings growth decelerationRevenue growing 12.5% YoY but earnings only +5.3%, suggesting rising costs are compressing net margin to 17.2%.
- moderateSequential revenue declineQoQ revenue growth of -1.4% signals near-term momentum stalling despite strong annual headline growth.
- moderateLow governance/value scoresACCE Growth score 52 and Value score 55 are below-average, suggesting limited near-term re-rating catalyst despite 18% discount to fair value.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
Price
Valuation
INVESTORSix independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.
- +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
- +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
- +Editable DCF workbench with saved scenarios
Quality
INVESTORThe full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.
- +Conviction score breakdown and earnings-quality grade
- +Growth / value / quality / momentum component scores
- +90-day score history and score-threshold backtests
Analysts
Wall Street consensus
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
- +Price-target low / average / high vs the current price, with implied upside
- +Forward revenue and EPS consensus by fiscal year
- +ACCE fair-value models lined up against the Street
Smart Money
PROFollow the institutions: 13F position changes, insider trades, and active 13D activist filings.
- +Quarter-over-quarter institutional position changes
- +Recent open-market insider transactions
- +Active 13D activist filings and top holders
Compare
Where it sits vs peers
Algorithmic peers (6)
| Ticker | Company | Mcap | P/E | ROE | D/E | Yield | Quality | |
|---|---|---|---|---|---|---|---|---|
| AZN.L | AstraZeneca | $258.7B | 25.0 | 22.0% | 0.57 | 2.6% | - | Compare |
| NOVN.SW | Novartis | $265.0B | 21.0 | 30.3% | 0.73 | 4.0% | - | Compare |
| NVS | Novartis AG Common Stock | $266.8B | 21.2 | 30.3% | 0.73 | 3.4% | - | Compare |
| AMGN | Amgen Inc. Common Stock | $208.5B | 24.0 | 91.5% | 6.31 | 2.6% | - | Compare |
| NVO | Novo Nordisk A/S Common Stock | $191.0B | 10.7 | 59.8% | 0.67 | 4.2% | - | Compare |
| NOVO-B.CO | Novo Nordisk B | $190.7B | 10.7 | 59.8% | 0.63 | 4.2% | - | Compare |
Sector report card
Where AZN ranks against its sector peers on each metric.
News and Record
Press releases mentioning this company
- GlobeNewswire•Sep 17, 2026Onco360® Has Been Selected as a National Pharmacy Partner for ETCAMAH™ (camizestrant)
- Business Wire•Sep 17, 2026Big Picture Bio Founded to Identify, Design and Optimise Promising Cancer Combination Therapies
- GlobeNewswire•Sep 17, 2026Tarja Stenvall Appointed Chief Executive Officer of Bavarian Nordic
Ask anything, Pro feature
Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.